Concepts (150)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Kidney Injury | 5 | 2024 | 695 | 0.700 |
Why?
|
| Urethral Obstruction | 5 | 2023 | 56 | 0.670 |
Why?
|
| Fetal Diseases | 5 | 2023 | 440 | 0.580 |
Why?
|
| Kidney | 7 | 2023 | 1278 | 0.360 |
Why?
|
| Renal Replacement Therapy | 4 | 2024 | 164 | 0.340 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2011 | 18 | 0.340 |
Why?
|
| Multiple Organ Failure | 2 | 2024 | 144 | 0.310 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2023 | 1267 | 0.310 |
Why?
|
| Critical Illness | 3 | 2024 | 617 | 0.300 |
Why?
|
| Urologic Diseases | 2 | 2019 | 42 | 0.270 |
Why?
|
| Graft Rejection | 1 | 2011 | 558 | 0.250 |
Why?
|
| Kidney Transplantation | 2 | 2017 | 560 | 0.250 |
Why?
|
| Complement Inactivating Agents | 1 | 2026 | 14 | 0.240 |
Why?
|
| Atypical Hemolytic Uremic Syndrome | 1 | 2026 | 13 | 0.240 |
Why?
|
| Immunotherapy | 2 | 2021 | 758 | 0.240 |
Why?
|
| Failure to Thrive | 1 | 2024 | 87 | 0.210 |
Why?
|
| Nephrosis, Lipoid | 1 | 2023 | 11 | 0.200 |
Why?
|
| Acidosis | 1 | 2024 | 97 | 0.200 |
Why?
|
| Nephrotic Syndrome | 1 | 2023 | 53 | 0.200 |
Why?
|
| Nephrocalcinosis | 1 | 2023 | 9 | 0.190 |
Why?
|
| Ultrasonography, Prenatal | 5 | 2023 | 973 | 0.190 |
Why?
|
| Nephrolithiasis | 1 | 2023 | 12 | 0.190 |
Why?
|
| Kidney Calculi | 1 | 2023 | 40 | 0.180 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2026 | 566 | 0.170 |
Why?
|
| Kidney Diseases | 2 | 2023 | 472 | 0.170 |
Why?
|
| Retrospective Studies | 10 | 2026 | 17554 | 0.170 |
Why?
|
| Nephrology | 1 | 2023 | 159 | 0.170 |
Why?
|
| Transfusion Reaction | 1 | 2021 | 42 | 0.170 |
Why?
|
| Urinary Bladder | 2 | 2023 | 220 | 0.160 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2019 | 15 | 0.150 |
Why?
|
| Optical Imaging | 2 | 2017 | 76 | 0.150 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2019 | 44 | 0.150 |
Why?
|
| Brain Injuries | 1 | 2025 | 703 | 0.150 |
Why?
|
| Renal Insufficiency | 2 | 2023 | 256 | 0.150 |
Why?
|
| Intensive Care Units, Pediatric | 2 | 2020 | 493 | 0.150 |
Why?
|
| Critical Care | 1 | 2025 | 684 | 0.150 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 310 | 0.150 |
Why?
|
| Nervous System Malformations | 1 | 2020 | 136 | 0.140 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2019 | 253 | 0.140 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 264 | 0.140 |
Why?
|
| Hyperglycemic Hyperosmolar Nonketotic Coma | 1 | 2017 | 9 | 0.140 |
Why?
|
| Patient Selection | 1 | 2021 | 720 | 0.130 |
Why?
|
| Child | 10 | 2026 | 26100 | 0.130 |
Why?
|
| Lymphedema | 1 | 2017 | 19 | 0.130 |
Why?
|
| Kidney Failure, Chronic | 2 | 2023 | 939 | 0.130 |
Why?
|
| Tissue Survival | 1 | 2017 | 7 | 0.130 |
Why?
|
| Humans | 24 | 2026 | 130496 | 0.130 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 160 | 0.120 |
Why?
|
| Intraoperative Care | 1 | 2017 | 121 | 0.120 |
Why?
|
| Perforator Flap | 1 | 2016 | 8 | 0.120 |
Why?
|
| Oxyhemoglobins | 1 | 2016 | 25 | 0.120 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 218 | 0.120 |
Why?
|
| Vascular Diseases | 1 | 2017 | 152 | 0.120 |
Why?
|
| Models, Animal | 1 | 2017 | 451 | 0.120 |
Why?
|
| Pregnancy | 7 | 2023 | 7408 | 0.120 |
Why?
|
| Female | 14 | 2026 | 70401 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1291 | 0.110 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2021 | 673 | 0.110 |
Why?
|
| Infant | 7 | 2026 | 13234 | 0.110 |
Why?
|
| Fetoscopy | 1 | 2017 | 469 | 0.090 |
Why?
|
| Skin | 1 | 2016 | 540 | 0.090 |
Why?
|
| Brain | 1 | 2025 | 3165 | 0.090 |
Why?
|
| Oxygen | 1 | 2016 | 551 | 0.090 |
Why?
|
| Adolescent | 8 | 2026 | 20739 | 0.090 |
Why?
|
| Severity of Illness Index | 4 | 2021 | 3041 | 0.080 |
Why?
|
| Young Adult | 5 | 2024 | 10010 | 0.080 |
Why?
|
| Adult | 7 | 2024 | 31183 | 0.080 |
Why?
|
| Drug Monitoring | 2 | 2026 | 287 | 0.080 |
Why?
|
| Fetus | 2 | 2023 | 566 | 0.080 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 666 | 0.070 |
Why?
|
| Graft Survival | 1 | 2011 | 459 | 0.070 |
Why?
|
| Child, Preschool | 5 | 2026 | 14946 | 0.070 |
Why?
|
| Amniotic Fluid | 2 | 2020 | 146 | 0.070 |
Why?
|
| Male | 9 | 2026 | 64498 | 0.070 |
Why?
|
| Oligohydramnios | 2 | 2019 | 46 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 1076 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 2564 | 0.060 |
Why?
|
| Ultrasonography | 2 | 2023 | 956 | 0.060 |
Why?
|
| Neoplasms | 1 | 2021 | 2955 | 0.060 |
Why?
|
| Complement System Proteins | 1 | 2026 | 59 | 0.060 |
Why?
|
| Remission Induction | 1 | 2026 | 303 | 0.060 |
Why?
|
| Gestational Age | 2 | 2020 | 1209 | 0.050 |
Why?
|
| Organ Dysfunction Scores | 1 | 2024 | 53 | 0.050 |
Why?
|
| Prevalence | 1 | 2011 | 2699 | 0.050 |
Why?
|
| Swine | 2 | 2017 | 1185 | 0.050 |
Why?
|
| Bicarbonates | 1 | 2023 | 98 | 0.050 |
Why?
|
| Steroids | 1 | 2023 | 169 | 0.050 |
Why?
|
| Renal Dialysis | 2 | 2023 | 948 | 0.050 |
Why?
|
| Diarrhea | 1 | 2024 | 314 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2017 | 1450 | 0.050 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2023 | 82 | 0.050 |
Why?
|
| Biomarkers | 2 | 2023 | 3388 | 0.040 |
Why?
|
| Infant, Newborn | 3 | 2020 | 8518 | 0.040 |
Why?
|
| Transfusion-Related Acute Lung Injury | 1 | 2021 | 2 | 0.040 |
Why?
|
| Prenatal Care | 1 | 2023 | 346 | 0.040 |
Why?
|
| Polydeoxyribonucleotides | 1 | 2019 | 3 | 0.040 |
Why?
|
| Tomography, Optical Coherence | 1 | 2025 | 451 | 0.040 |
Why?
|
| Caribbean Region | 1 | 2019 | 19 | 0.040 |
Why?
|
| Cholagogues and Choleretics | 1 | 2019 | 24 | 0.040 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2019 | 38 | 0.040 |
Why?
|
| Perinatal Mortality | 1 | 2019 | 44 | 0.040 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 126 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2021 | 190 | 0.040 |
Why?
|
| Age of Onset | 1 | 2021 | 596 | 0.040 |
Why?
|
| Consensus | 1 | 2021 | 529 | 0.040 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2019 | 160 | 0.040 |
Why?
|
| Bilirubin | 1 | 2019 | 126 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2024 | 1880 | 0.040 |
Why?
|
| Ultrasonography, Doppler | 1 | 2019 | 185 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2019 | 191 | 0.030 |
Why?
|
| Homozygote | 1 | 2019 | 539 | 0.030 |
Why?
|
| Electrolytes | 1 | 2017 | 59 | 0.030 |
Why?
|
| Cystoscopy | 1 | 2017 | 41 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2021 | 796 | 0.030 |
Why?
|
| Exons | 1 | 2019 | 765 | 0.030 |
Why?
|
| Ascites | 1 | 2017 | 98 | 0.030 |
Why?
|
| beta 2-Microglobulin | 1 | 2016 | 35 | 0.030 |
Why?
|
| Coloring Agents | 1 | 2017 | 70 | 0.030 |
Why?
|
| Anastomosis, Surgical | 1 | 2017 | 176 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 2016 | 146 | 0.030 |
Why?
|
| Indocyanine Green | 1 | 2017 | 51 | 0.030 |
Why?
|
| Chlorides | 1 | 2016 | 97 | 0.030 |
Why?
|
| Angiography | 1 | 2017 | 181 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2017 | 364 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2023 | 1101 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2017 | 330 | 0.030 |
Why?
|
| Sodium | 1 | 2016 | 278 | 0.030 |
Why?
|
| Surgical Flaps | 1 | 2017 | 179 | 0.030 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2016 | 157 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2024 | 5081 | 0.030 |
Why?
|
| Peritoneal Dialysis | 1 | 2016 | 132 | 0.030 |
Why?
|
| Age Factors | 1 | 2021 | 2839 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2017 | 1106 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 3807 | 0.030 |
Why?
|
| Disease Management | 1 | 2017 | 556 | 0.020 |
Why?
|
| Prenatal Diagnosis | 1 | 2016 | 615 | 0.020 |
Why?
|
| Pediatrics | 1 | 2021 | 1243 | 0.020 |
Why?
|
| Calcium | 1 | 2016 | 1028 | 0.020 |
Why?
|
| Animals | 3 | 2017 | 33855 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 2300 | 0.020 |
Why?
|
| Rats | 1 | 2017 | 3380 | 0.020 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 849 | 0.020 |
Why?
|
| Middle Aged | 1 | 2011 | 28448 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2908 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2026 | 12850 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2019 | 3680 | 0.020 |
Why?
|
| Phenotype | 1 | 2019 | 4479 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 6206 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 3751 | 0.010 |
Why?
|
| Risk Factors | 1 | 2019 | 10959 | 0.010 |
Why?
|